{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:08:09Z","timestamp":1792267689661,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2023CXA022"],"award-info":[{"award-number":["2023CXA022"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01474-2","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:06:15Z","timestamp":1778483175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multi-omics profiling reveals tumor microenvironment characteristics linked to immunotherapy response and prognosis in non-small cell lung cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Liangyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkai","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fancai","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"1474_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1474_CR2","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","volume":"378","author":"P Goldstraw","year":"2011","unstructured":"Goldstraw, P. et al. Non-small-cell lung cancer. Lancet (Lond., Engl.) 378, 1727\u20131740 (2011).","journal-title":"Lancet (Lond., Engl.)"},{"key":"1474_CR3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet (Lond., Engl.) 393, 1819\u20131830 (2019).","journal-title":"Lancet (Lond., Engl.)"},{"key":"1474_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri, A. et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol. cancer 22, 40 (2023).","journal-title":"Mol. cancer"},{"key":"1474_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck, M., Remon, J. & Hellmann, M. D. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J. Clin. Oncol. 40, 586\u2013597 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1474_CR6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1474_CR7","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1200\/JCO.22.00873","volume":"40","author":"A Passaro","year":"2022","unstructured":"Passaro, A., Attili, I. & de Marinis, F. Neoadjuvant chemotherapy plus immunotherapy in early-stage resectable non-small-cell lung cancer. J. Clin. Oncol. 40, 2871\u20132877 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1474_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang, J. Y. et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: An open-label, randomised, phase 2 trial. Lancet (Lond., Engl.) 402, 871\u2013881 (2023).","journal-title":"Lancet (Lond., Engl.)"},{"key":"1474_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"NK Altorki","year":"2019","unstructured":"Altorki, N. K. et al. The lung microenvironment: An important regulator of tumour growth and metastasis. Nat. Rev. Cancer 19, 9\u201331 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"1474_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"1474_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"1474_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","journal-title":"Nature"},{"key":"1474_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41592-019-0691-5","volume":"17","author":"C Zhu","year":"2020","unstructured":"Zhu, C., Preissl, S. & Ren, B. Single-cell multimodal omics: the power of many. Nat. methods 17, 11\u201314 (2020).","journal-title":"Nat. methods"},{"key":"1474_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41576-019-0093-7","volume":"20","author":"T Stuart","year":"2019","unstructured":"Stuart, T. & Satija, R. Integrative single-cell analysis. Nat. Rev. Genet. 20, 257\u2013272 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"1474_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-021-01105-2","volume":"14","author":"Y Lei","year":"2021","unstructured":"Lei, Y. et al. Applications of single-cell sequencing in cancer research: progress and perspectives. J. Hematol. Oncol. 14, 91 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"1474_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41419-022-05057-4","volume":"13","author":"Z Hui","year":"2022","unstructured":"Hui, Z. et al. Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). Cell Death Dis. 13, 607 (2022).","journal-title":"Cell Death Dis."},{"key":"1474_CR17","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA: A Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA: A Cancer J. Clin."},{"key":"1474_CR18","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1474_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"1474_CR20","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (Lond., Engl.) 387, 1540\u20131550 (2016).","journal-title":"Lancet (Lond., Engl.)"},{"key":"1474_CR21","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830.e14 (2018).","journal-title":"Immunity"},{"key":"1474_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1474_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen, K. C. et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat. Med. 26, 693\u2013698 (2020).","journal-title":"Nat. Med."},{"key":"1474_CR24","doi-asserted-by":"crossref","unstructured":"Zhang, C. et al. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. J. Immunother. Cancer. 9, e002312 (2021).","DOI":"10.1136\/jitc-2020-002312"},{"key":"1474_CR25","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u201397.e24 (2018).","journal-title":"Cell"},{"key":"1474_CR26","doi-asserted-by":"crossref","unstructured":"Sade-Feldman, M. et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 175, 998\u20131013.e20 (2018).","DOI":"10.1016\/j.cell.2018.10.038"},{"key":"1474_CR27","doi-asserted-by":"crossref","unstructured":"Yomogida, K. et al. Hobit confers tissue-dependent programs to type 1 innate lymphoid cells. Proc. Natl. Acad. Sci. USA 118, e2117965118 (2021).","DOI":"10.1073\/pnas.2117965118"},{"key":"1474_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1474652","volume":"15","author":"M Khan","year":"2024","unstructured":"Khan, M. et al. Transcriptional signature of CD56(bright) NK cells predicts favourable prognosis in bladder cancer. Front. Immunol. 15, 1474652 (2024).","journal-title":"Front. Immunol."},{"key":"1474_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1126\/science.aad2035","volume":"352","author":"LK Mackay","year":"2016","unstructured":"Mackay, L. K. et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Sci. (N. Y., NY) 352, 459\u2013463 (2016).","journal-title":"Sci. (N. Y., NY)"},{"key":"1474_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature24993","volume":"552","author":"JJ Milner","year":"2017","unstructured":"Milner, J. J. et al. Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours. Nature 552, 253\u2013257 (2017).","journal-title":"Nature"},{"key":"1474_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.immuni.2014.12.007","volume":"41","author":"JM Schenkel","year":"2014","unstructured":"Schenkel, J. M. & Masopust, D. Tissue-resident memory T cells. Immunity 41, 886\u2013897 (2014).","journal-title":"Immunity"},{"key":"1474_CR32","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1172\/JCI42758","volume":"120","author":"KM Hertoghs","year":"2010","unstructured":"Hertoghs, K. M. et al. Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J. Clin. Investig. 120, 4077\u20134090 (2010).","journal-title":"J. Clin. Investig."},{"key":"1474_CR33","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/ni.2393","volume":"13","author":"KP van Gisbergen","year":"2012","unstructured":"van Gisbergen, K. P. et al. Mouse Hobit is a homolog of the transcriptional repressor Blimp-1 that regulates NKT cell effector differentiation. Nat. Immunol. 13, 864\u2013871 (2012).","journal-title":"Nat. Immunol."},{"key":"1474_CR34","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ccell.2023.08.013","volume":"41","author":"EM Parry","year":"2023","unstructured":"Parry, E. M. et al. ZNF683 marks a CD8(+) T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer cell 41, 1803\u20131816.e8 (2023).","journal-title":"Cancer cell"},{"key":"1474_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.yexcr.2017.08.028","volume":"359","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y., Du, W., Chen, Z. & Xiang, C. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. Exp. cell Res. 359, 449\u2013457 (2017).","journal-title":"Exp. cell Res."},{"key":"1474_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-1-4939-3578-9_6","volume":"1418","author":"Z Wang","year":"2016","unstructured":"Wang, Z., Jensen, M. A. & Zenklusen, J. C. A Practical Guide to The Cancer Genome Atlas (TCGA). Methods Mol. Biol. 1418, 111\u2013141 (2016).","journal-title":"Methods Mol. Biol."},{"key":"1474_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-4939-3578-9_5","volume":"1418","author":"E Clough","year":"2016","unstructured":"Clough, E. & Barrett, T. The gene expression omnibus database. Methods Mol. Biol. 1418, 93\u2013110 (2016).","journal-title":"Methods Mol. Biol."},{"key":"1474_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.gpb.2022.08.004","volume":"21","author":"Z Chen","year":"2023","unstructured":"Chen, Z. et al. TIGER: A web portal of tumor immunotherapy gene expression resource. Genomics, Proteom. Bioinforma. 21, 337\u2013348 (2023).","journal-title":"Genomics, Proteom. Bioinforma."},{"key":"1474_CR39","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1474_CR40","doi-asserted-by":"crossref","unstructured":"Shiuan, E. et al. Clinical features and multiplatform molecular analysis assist in understanding patient response to anti-PD-1\/PD-L1 in renal cell carcinoma. Cancers (Basel). 13, 1475 (2021).","DOI":"10.3390\/cancers13061475"},{"key":"1474_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","volume":"5","author":"T Nathanson","year":"2017","unstructured":"Nathanson, T. et al. Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol. Res. 5, 84\u201391 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"1474_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"1474_CR43","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"1474_CR44","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun, D. et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic acids Res. 49, D1420\u2013d30 (2021).","journal-title":"Nucleic acids Res."},{"key":"1474_CR45","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888\u2013902.e21 (2019).","journal-title":"Cell"},{"key":"1474_CR46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"1474_CR47","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/s41596-020-0336-2","volume":"15","author":"B Van de Sande","year":"2020","unstructured":"Van de Sande, B. et al. A scalable SCENIC workflow for single-cell gene regulatory network analysis. Nat. Protoc. 15, 2247\u20132276 (2020).","journal-title":"Nat. Protoc."},{"key":"1474_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.919731","volume":"10","author":"Z Fang","year":"2022","unstructured":"Fang, Z. et al. Single-cell transcriptomics of proliferative phase endometrium: Systems analysis of cell-cell communication network using cellchat. Front. Cell Dev. Biol. 10, 919731 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1474_CR49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381\u2013386 (2014).","journal-title":"Nat. Biotechnol."},{"key":"1474_CR50","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"1474_CR51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.aax0249","volume":"367","author":"GS Gulati","year":"2020","unstructured":"Gulati, G. S. et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Sci. (N. Y., NY) 367, 405\u2013411 (2020).","journal-title":"Sci. (N. Y., NY)"},{"key":"1474_CR52","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: An R package for comparing biological themes among gene clusters. Omics 16, 284\u2013287 (2012).","journal-title":"Omics"},{"key":"1474_CR53","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248\u2013262 (2017).","journal-title":"Cell Rep."},{"key":"1474_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y \u015eenbabao\u011flu","year":"2016","unstructured":"\u015eenbabao\u011flu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016).","journal-title":"Genome Biol."},{"key":"1474_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687975","volume":"12","author":"D Zeng","year":"2021","unstructured":"Zeng, D. et al. IOBR: Multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front. Immunol. 12, 687975 (2021).","journal-title":"Front. Immunol."}],"updated-by":[{"DOI":"10.1038\/s41698-026-01540-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000}}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01474-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:02:37Z","timestamp":1780729357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01474-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01474-2","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41698-026-01540-9","URL":"https:\/\/doi.org\/10.1038\/s41698-026-01540-9","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The content of this manuscript has not been previously published and is not under consideration for publication elsewhere. All authors consent for publication in this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"179"}}